- Home
- ARR vs PHVS Comparison
ARR vs PHVS Comparison
Compare ARR & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARR
- PHVS
- Stock Information
- Founded
- ARR 2008
- PHVS 2015
- Country
- ARR United States
- PHVS Switzerland
- Employees
- ARR N/A
- PHVS N/A
- Industry
- ARR Real Estate Investment Trusts
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- ARR Real Estate
- PHVS Health Care
- Exchange
- ARR Nasdaq
- PHVS Nasdaq
- Market Cap
- ARR 1.8B
- PHVS 1.6B
- IPO Year
- ARR N/A
- PHVS 2021
- Fundamental
- Price
- ARR $15.63
- PHVS $22.31
- Analyst Decision
- ARR Buy
- PHVS Buy
- Analyst Count
- ARR 4
- PHVS 4
- Target Price
- ARR $15.50
- PHVS $33.00
- AVG Volume (30 Days)
- ARR 3.5M
- PHVS 222.4K
- Earning Date
- ARR 10-22-2025
- PHVS 11-12-2025
- Dividend Yield
- ARR 18.47%
- PHVS N/A
- EPS Growth
- ARR N/A
- PHVS N/A
- EPS
- ARR N/A
- PHVS N/A
- Revenue
- ARR $20,589,000.00
- PHVS N/A
- Revenue This Year
- ARR $350.86
- PHVS N/A
- Revenue Next Year
- ARR $54.46
- PHVS N/A
- P/E Ratio
- ARR N/A
- PHVS N/A
- Revenue Growth
- ARR N/A
- PHVS N/A
- 52 Week Low
- ARR $13.18
- PHVS $11.51
- 52 Week High
- ARR $20.39
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- ARR 61.38
- PHVS 41.09
- Support Level
- ARR $14.00
- PHVS $22.71
- Resistance Level
- ARR $15.73
- PHVS $24.01
- Average True Range (ATR)
- ARR 0.31
- PHVS 1.25
- MACD
- ARR 0.15
- PHVS -0.31
- Stochastic Oscillator
- ARR 96.42
- PHVS 3.28
About ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.